Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

2.

BRAF mutation in thyroid cancer.

Xing M.

Endocr Relat Cancer. 2005 Jun;12(2):245-62. Review.

3.

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Xing M.

Endocr Rev. 2007 Dec;28(7):742-62. Epub 2007 Oct 16. Review.

PMID:
17940185
4.

Role of BRAF in thyroid oncogenesis.

Caronia LM, Phay JE, Shah MH.

Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Epub 2011 Sep 7. Review.

5.

BRAF mutations in papillary thyroid carcinoma.

Wojciechowska K, Lewinski A.

Endocr Regul. 2006 Dec;40(4):129-38. Review.

PMID:
17201587
6.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Review. Spanish.

PMID:
19627734
7.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

8.

Clinical prognosis in BRAF-mutated PTC.

Puxeddu E, Moretti S.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. Review.

9.

Molecular diagnostics of thyroid tumors.

Nikiforov YE.

Arch Pathol Lab Med. 2011 May;135(5):569-77. doi: 10.1043/2010-0664-RAIR.1. Review.

PMID:
21526955
10.

Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.

Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P.

Curr Med Chem. 2010;17(17):1839-50. Review.

PMID:
20345340
11.

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).

Leonardi GC, Candido S, Carbone M, Raiti F, Colaianni V, Garozzo S, Cinà D, McCubrey JA, Libra M.

Mol Med Rep. 2012 Oct;6(4):687-94. doi: 10.3892/mmr.2012.1016. Epub 2012 Aug 2. Review.

PMID:
22858857
12.

[BRAF gene mutation in thyroid cancer].

Kopczyńska E, Junik R, Tyrakowski T.

Pol Merkur Lekarski. 2006 Feb;20(116):210-3. Review. Polish.

PMID:
16708643
13.

[BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].

Lopes JP, Fonseca E.

Acta Med Port. 2011 Dec;24 Suppl 4:855-68. Epub 2011 Dec 31. Review. Portuguese.

14.

Alterations of the BRAF gene in thyroid tumors.

Ciampi R, Nikiforov YE.

Endocr Pathol. 2005 Fall;16(3):163-72. Review.

PMID:
16299399
15.

Targeting of the BRAF gene in papillary thyroid carcinoma (review).

Li Y, Nakamura M, Kakudo K.

Oncol Rep. 2009 Oct;22(4):671-81. Review.

PMID:
19724843
16.

Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.

Nikiforova MN, Nikiforov YE.

Expert Rev Mol Diagn. 2008 Jan;8(1):83-95. Review.

PMID:
18088233
17.

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Ciampi R, Nikiforov YE.

Endocrinology. 2007 Mar;148(3):936-41. Epub 2006 Aug 31. Review.

PMID:
16946010
18.

Prognostic utility of BRAF mutation in papillary thyroid cancer.

Xing M.

Mol Cell Endocrinol. 2010 May 28;321(1):86-93. doi: 10.1016/j.mce.2009.10.012. Epub 2009 Oct 31. Review.

19.

The role of BRAF in the pathogenesis of thyroid carcinoma.

Li DD, Zhang YF, Xu HX, Zhang XP.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1068-78. Review.

PMID:
25961545
20.

Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.

Handkiewicz-Junak D, Czarniecka A, Jarzab B.

Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28. doi: 10.1016/j.mce.2010.01.007. Epub 2010 Feb 4. Review.

PMID:
20138116

Supplemental Content

Support Center